Allogeneic bone marrow transplantation (BMT) with marrow ablative conditioning is the treatment of choice for haematopoietic malignancies. The use of nonmyeloablative stem cell transplants has allowed the treatment of patients previously ineligible for BMT because of age or other disease. These reduced conditioning regimes allow the persistence initially of some recipient cells in the blood and bone marrow (haematopoietic chimaerism). Monitoring of the relative proportion of donor and recipient cells is required to assess the success of the procedure, to predict subsequent rejection or impending relapse and to guide the use of donor lymphocyte infusions. We present a quantitative real-time PCR approach for the measurement of haematopoietic chimaerism using the TaqMant. This approach exploits the presence of singlenucleotide polymorphisms (SNPs) to distinguish cells of patient or donor origin. We have designed and validated a panel of seven allele-specific probes to quantify the contribution of patient and donor cells in the haematopoietic population from 12 patient and donor pairs. We have compared the performance of this approach with an existing method and proved it to be superior in both accuracy and sensitivity. The use of more sensitive and accurate techniques permits earlier intervention for improved clinical outcome.
Allogeneic bone marrow transplantation (BMT) is the treatment of choice for a wide range of haematopoietic disorders. Traditionally, the patient has been subjected to high-dose conditioning regimes prior to transplantation. The intense nature of this treatment has rendered a large number of patients unsuitable for treatment by virtue of age (graft-versus-host disease (GVHD) is more common in patients over 55 years old) or underlying organ damage. Mortality in the first 100 days post transplant depends on a number of factors. Overall mortality is around 10-15%, but in some situations can be as high as 30-50%. 1 The finding that the remissions were not solely due to the cytotoxic effects of the conditioning but were also a product of a graft-versus-leukaemia (CVL) effect 2 has allowed the use of less-intensive procedures such as nonmyeloablative stem cell transplant 3, 4 or reduced conditioning allograft. However, disease relapse, graft rejection and GVHD remain a considerable problem. The persistence or reappearance of recipient cells (mixed chimaerism; MC) following nonmyeloablative SCT has been associated with impending relapse, 5, 6 increased risk of GVHD 7 and graft failure. 8 Conversely, persistent full donor chimaerism is consistent with disease free-survival. 9 Khan et al 10 have recently highlighted the importance of chimaerism monitoring for prediction of such adverse events.
Methods of determining the persistence of patient cells in the population have been recently reviewed by Thiede 11 and include RFLP analysis, 12 VNTR analysis, 13 sex-specific mismatch 14 and microsatellite analysis. 15, 16 The sensitivities of these techniques vary greatly. Minisatellite and microsatellite analysis are the most widely used, with accuracy and sensitivity estimated between 0.1 and 5% patient cells. 9, 13, 15, [17] [18] [19] However, the accuracy of this approach is dependent on the choice of marker, since measurements may be complicated by the presence of 'stutter' peaks arising from slippage of the DNA polymerase during PCR. For this reason, tetranucleotide repeats are preferred to dinucleotide markers and the discriminant allele should not be the same size as any stutter peak.
An alternative source of genetic variation between patients and donors are single-nucleotide polymorphisms (SNPs). The majority of SNPs are biallelic (they exist as two forms differing at a single nucleotide position) and they are present at approximately 1 SNP per 1000 bases throughout the human genome. 20 Identification of SNP differences between patient and donor can be used to identify the origin of cells within a population. SNP differences between individuals have recently been used in microarray-based minisequencing 21 and pyrosequencing 22 approaches to determine chimaerism status. In these studies, data produced from SNP analysis correlated well with that obtained from examination of microsatellites. 21 The recent application of real-time PCR has allowed accurate quantitation of nucleic acids. 23 Real-time PCR using the ABI TaqMant Prism 7000 instrument relies upon the detection of PCR products during the elongation phase of amplification by the binding of allele-specific probes to target sequences. The probes are labelled 5 0 with a fluorochrome and 3 0 with a nonfluorescent quencher molecule, and are quiescent when in free solution. Where probes are perfectly bound, cleavage of the fluorochrome from the quencher during PCR produces a fluorescent signal. The level of fluorescence is a direct measurement of the amount of template. The starting concentrations of any given fragment can be determined as a function of the point at which the fluorescent signal becomes visible above the background (crossing point; C t ). This SNPtyping approach can be used to detect haematopoietic chimaerism. 11, [24] [25] [26] In the current study, we exploit the presence of SNPs to identify differences between patient and donor. We present a panel of allele-specific TaqMant probes to assess chimaerism in post transplant patient samples. We compare results achieved with the microsatellite approach with those achieved from real-time PCR analysis from artificial chimaeric mixtures of known composition. This assay permits the rapid, accurate and sensitive quantitation of haematopoietic chimaerism from both blood and bone marrow in patients following BMT.
Patients, materials and methods

Patients
Six bone marrow samples and 33 peripheral blood samples were received from patients referred for nonmyeloablative SCT from the Royal Devon and Exeter NHS trust and Plymouth Hospitals NHS trust as part of their routine post transplant monitoring. We analysed 12 patient:donor pairs. Both sibling (n ¼ 9) and unrelated donors were represented (n ¼ 3). Patient diagnoses included AML (n ¼ 6), CML (n ¼ 3), NHL (n ¼ 1) HL (n ¼ 1) and MCL (n ¼ 1).
Sample preparation
DNA was extracted from peripheral blood and bone marrow aspirates by previously described techniques. 27 The concentration of DNA was measured by UV spectrophotometry.
Microsatellite analysis
Samples were analysed for MC by the use of a multiplex PCR containing primers for seven microsatellite loci and one set of primers for the amelogenin gene that distinguishes X and Y sequences (Table 1a) . Briefly, PCR reactions contained 1.5 mM MgCl 2, 0.8 mM dNTPs (ABgene, Epsom, UK), 0.5 U Taq polymerase (ABI, Warrington, UK) and 40 ng DNA in a total volume of 25 ml. Primer concentrations are given in Table 1a . PCR cycling conditions were a hot start of 951C for 10 min, followed by 12 cycles of 941C -30 s, 551C -30 s and 721C -1 min and 13 cycles of 891C -30 s, 551C -30 s and 721C -1 min. PCR products were analysed on an ABI 377 using Genotypert software (ABI, Warrington, UK).
Informative markers were identified and standard curves were constructed of 0, 1, 5, 10, 25, 50, 75 and 100% patient DNA diluted in donor DNA for each informative marker. PCRs were halted after 25 cycles to ensure that the reaction was in the exponential phase and the results would be quantitative. The percentage of patient cells was calculated as a function of the ratio of patient and donor peak areas for each dilution (SP/SD). The percentage of patient DNA for the test samples could then be determined from the graph (Figure 1 ).
Real-time assay development
SNPs were chosen from the dbSNP database 28 on the basis of biallelic status and high levels of heterozygosity in the population. We calculated that a marker with a frequency of 0.5 for each allele would be most informative. The TaqMant system relies upon competition for binding to target of a pair of probes, one specific for each allele. 23 The probes are labelled 5 0 with either 6-FAM or VIC. The incorporation of a 3 0 minor-groove-binding protein into the probe raises the melting temperature of the probe so that shorter and therefore more specific probes can be used. Specific TaqMant MGB assays were designed using the Assays-by-designt service from Applied Biosystems (TSC0955234, rs3918344 and rs338773) or by Primer Expresst software supplied with the instrument (TSC0005295, TSC0541887, Amelogenin and T515 29 ). Primer and probe sequences are given in Table 1b . The amelogenin assay necessitated the use of two alternate reverse primers in the reaction, as the X chromosome PCR product was too large for the TaqMant, which has an ideal amplicon size of less than 150 bp. Each probe pair was validated for accuracy by the construction of standard curves from serial dilutions of 8 ng to 250 pg. Each point on the curve was set up in triplicate to allow calculation of standard error. Probes were then validated for sensitivity by mixing experiments involving dilution of patient DNA in donor DNA. Specificity was determined by the use of 100% patient and 100% donor DNAs. Some crosstalk between dyes was expected but this was accounted for by colour compensation functions in the quantitation software.
Identification of informative markers for each patient
Patient:donor pairs were tested with the TaqMant probe panel to identify informative markers. Markers were determined to be informative if either the patient or the donor possessed a unique allele or alleles (ie heterozygosity or homozygosity for disparate alleles). PCRs were carried out in 25 ml reactions containing 12.5 ml TaqMant master mix (ABI, Foster City, USA), 200 nM each probe, 250 nM each primer and 50 ng DNA. Cycling conditions were: one cycle of 951C for 10 min, followed by 40 cycles of 951C for 15 s, 601C for 1 min.
Real time quantitative PCR
Real-time quantitative PCRs were carried out by standard TaqMant technology using the ABI PRISM 7000 platform. The signal produced by binding of the allele-specific probes was measured. The probes were labelled with two fluorochromes with different emission spectra to allow simultaneous amplification in a single tube. The fluorescent signal from each allele is proportional to the amount of product. The ABI PRISM 7000 calculates the point at which the fluorescence signal rises above the background; the crossing point (C t ). This is directly proportional to and thus a direct measure of the starting template.
We aimed to calculate the relative frequency of patient and donor DNA by identifying the relative ratio of alleles at the informative SNP. Where evidence of MC was found, standard curves were set up in triplicate for informative markers. Following PCR amplification, the quantity of each allele was determined from the standard curve derived by the TaqMant software. The percentage of heterozygous (H) and homozygous (h) DNA was calculated by the equation below, where R ¼ ratio of unique allele to common allele normalised to a heterozygous control, to account for slight differences in probing efficiency. The equation was derived from the proportion of unique alleles as a percentage of the total alleles, and the fact that the Table 1 Microsatellite unique allele must be paired with a common allele in an individual heterozygous at that locus.
H ¼ 2 100 100 þ ð100RÞ ð100RÞ
In a situation where patient (HH) and donor (hh) are homozygous for disparate alleles at a locus, the percentage of patient DNA is given by the equation given below.
HH ¼ 100 100 þ ð100RÞ ð100RÞ
Comparison of microsatellite and real-time PCR approaches
Artificial chimaeric mixtures were created using two DNA samples that were homozygous for different alleles of two SNPs and heterozygous for two microsatellite markers. The microsatellites included the tetranucleotide marker D20S481 and the dinucleotide marker D20S107. The informative 'patient' allele of D20S107 did not coincide with any stutter peak from the 'donor' alleles. The mixtures ranged from 0 to 100% of DNA sample 1 ('patient') relative to DNA sample 2 ('donor') using a total of 40 ng DNA. Triplicate PCRs were set up from the same chimaeric DNA samples by microsatellite and real-time methods. Analysis was carried out as described above.
Results
Assay design
We identified seven biallelic SNPs with a heterozygosity of approximately 50% in at least two ethnic groups. We designed assays only to SNPs for which genotyping data were available to avoid the selection of variants that might be present only in silico (ie variants present only in the database that probably represent sequence artefacts rather than true SNPs). If both homozygotes and heterozygotes are taken to be informative, an SNP with an allele frequency of 0.5 will be informative for 62.5% of patient: donor pairs. 24 Therefore, statistically, four loci should provide an informative marker in any situation, 24 although additional markers may be required for some patients. All assays designed from these SNPs produced reliable and specific amplification.
Validation of assay
The accuracy of each SNP assay was determined by serial dilution of heterozygous DNA. In addition, the specificity of probing was monitored by the inclusion of 100% patient and 100% donor DNA into the series. The standard curves produced were seen to be linear over all ranges with small variations in the C t values achieved for each dilution. All seven TaqMant assays yielded consistent and efficient amplification with no major variations in PCR or probing efficiency between alleles as shown by standard curve analysis. All assays proved sensitive to 250 pg of DNA (Figure 2a ). An optimally efficient PCR reaction yields a slope of À3. We determined the sensitivity of each SNP assay by artificial chimaeric mixtures (serial dilutions of patient DNA in donor DNA). Mixing experiments indicated that the assays are capable of accurately detecting 1% patient DNA (Figure 2b ).
Qualitative and quantitative analysis of unknown samples
To assess the performance of our assay in post transplant monitoring of haematopoietic chimaerism, we monitored 12 recipient:donor pairs over a period of 3 years (Table 2) . Initially, all 24 individuals were genotyped with each marker in the panel and also with a panel of microsatellite markers (Table 1b) . Figure 2c shows an example of genotyping data obtained with the SNP assay. All patient: donor pairs proved informative for at least one SNP and 92% of pairs were informative for two or more SNPs. In all, 92% of patient donor pairs were informative using this panel of seven microsatellite multiplex reaction and only one patient:donor pair (pair 9) required the use of an additional microsatellite. Sex mismatch was noted in 25% of patient:donor pairs. Post transplant samples for each recipient were analysed for evidence of MC using both realtime and microsatellite analysis. In total, 10/12 (83%) patients showed a full donor profile (FDP) at all times by both real-time and microsatellite analysis. Samples showing evidence of MC were then quantified by real-time PCR and microsatellite analysis. Mean error in quantitation of MC for the real-time PCR assay was 4.9% (range 2.0-11%). 
Comparison of microsatellite and real-time methods of quantitation
The composition of a series of artificial chimaeric mixtures was determined by microsatellite and real-time approaches.
The results are given in Figure 3a and b. There was some intermarker variation in the quantitation achieved by both methods. The correlation coefficient (r 2 ) between the calculated composition and the known composition was 0.994-0.998 for the real-time technique and 0.991-0.992 for the microsatellites, respectively. Comparison of intermarker variability revealed that the real-time method achieved reproducible and accurate results over all chimaeric ranges with r 2 values of ¼ 0.99, 0.99 and 0.99 for the total range, o20% target and 480% target, respectively. The microsatellite method performed well over the mid-range of target concentrations (r 2 ¼ 0.98) but proved less reliable at the extremes of the template range (target at o20 and 480% of the mixture) when r 2 was 0.80 and 0.96, respectively. Microsatellite D20S481 failed to detect any patient DNA below a threshold of 20% (see Figure 3a) .
Clinical results
We present two clinical situations in which the utility of our new approach is demonstrated. Case 1. Patient 12 is a 64-year-old man with CML. He underwent a nonmyeloablative SCT with an HLA-matched sibling donor. We analysed nine sequential blood samples. The patient showed a partial response accompanied by evidence of MC, which increased until week 14 post transplant. This correlated with the re-emergence of his disease. The patient was then treated with STI-571, which targets the t(9:22) translocation fusion product. He also received donor lymphocyte infusion (DLI) at week 14 after which a progressive decrease in mixed chimaerism was noted until a full donor profile was noted at week 19. He is currently asymptomatic and in full molecular and cytological remission as judged by absence of the t(9:22) translocation chromosome by fluorescence in situ hybridization (FISH) or reverse transcriptase (RT) PCR.
Case 2. Patient 8 is a 37-year-old man diagnosed with MCL. He underwent nonmyeloablative SCT treatment with an HLA-matched sibling donor. This patient also showed MC in both peripheral blood and bone marrow 10 weeks after transplant that persisted until week 22. Mixed chimaerism was more marked in the bone marrow (57% patient cells) than the peripheral blood (37% patient cells) at week 10. He received a DLI at this point and showed a full donor profile in samples taken at week 42 and week 70 post transplant.
Discussion
We have developed a novel quantitative real-time PCR technique to rapidly and accurately detect and monitor the incidence of MC in patients following nonmyeloablative SCT BMT. An increasing degree of MC has been correlated with impending relapse, 5,6 GVHD 7 and graft failure 8 in a number of studies. Analysis of lineage-specific samples may prove especially useful since mixed chimaerism is often more prevalent in T-cell-depleted samples. 6, 16, 30 Any method of assessing haematopoietic chimaerism must be fast, sensitive, accurate and applicable to all patients regardless of disease or relationship to donor. Methods such as RFLP analysis, 12 VNTR analysis, 13 sex-specific mismatch 14 and microsatellite analysis 15, 16 have been used to monitor MC but these methods lack the accuracy of quantitation and speed of real-time PCR.
SNPs are particularly useful for chimaerism analysis because the differentiation between patient and donor is based on interindividual variation and does not rely on disease-specific markers. The high information content of the SNP panel means that any two individuals can in theory be distinguished. For example, Hochberg et al 22 were able to distinguish at least one informative locus in 55 patients with HLA-identical donors with a panel of 14 SNPs. 22 Other SNP-based approaches using microarray-based minisequencing 21 or pyrosequencing 22 techniques have proved superior to microsatellite methods on the basis of turnaround time or accuracy, but are less sensitive than real-time PCR methods. For example, a pyrosequencing technique had a reported detection limit of 5%. 22 Real-time PCR has previously been used to monitor the CML specific t(9:22) fusion product. 31, 32 Other studies have used the polymorphic cytochrome P450 CYP2C9 gene and used end point measurements for quantitation of mixed chimaerism. 24 It is now well recognised that crossing points give a more accurate determination of starting template than end point measurements. 23 Subsequent studies produced a large panel of SNP-based TaqMant probes but discriminated patient and donor on the basis of allelespecific amplification detected with a common probe. 25, 26 The use of allele-specific oligonucleotides in both these studies permits allele discrimination but raises the caveat that alleles may not be amplified equally due to differences in the efficiency of the PCR. Using this approach Maas et al 26 found high standard errors in cases where the contribution of patient cells to the DNA population was elevated, necessitating the use of two separate standard curves to accurately determine the degree of MC. 26 The use of common primers and an allele-specific probe system represents an improvement on current methods since the detection and quantification of patient and donor DNA is independent of PCR efficiency. Our approach allows the quantitation of one allele relative to the other in the same tube from a single standard curve. The use of a single common pair of primers and a single tube approach effectively controls for PCR inhibitors, differences in template input and allows more accurate quantitation.
We have performed a comparison between the use of microsatellites and SNPs to distinguish DNA from two origins for the purposes of chimaerism analysis. The amount of patient cells present in a series of artificial chimaeras was determined by both approaches. Both methods performed well over the middle of the measured target range, but the microsatellite approach was less accurate at either low or high target concentrations. Although general estimates of the linear range of microsatellite markers cannot be drawn from studies of single microsatellites, intermarker variation is apparent (see Figure 3a) . The linear range for the trinucleotide repeat microsatellite D2S206 as tested here is only between approximately 25 and 75% (Figure 1 ). In contrast, the standard curve produced by our novel TaqMant technique is reliably linear over all ranges. This has clinical importance in that patients who may be about to relapse (with low but increasing amounts of MC) may not be accurately identified by microsatellite methods. We believe that due to its superior sensitivity, real-time PCR is the method of choice for chimaerism-based minimal residual disease monitoring. The application of the new technique in lineage-specific studies may increase the sensitivity of the approach further.
To conclude, we report a new method for the evaluation of haematopoietic chimaerism following BMT. This method is fast, accurate and sensitive. Improved quantitation of the persistance or re-emergence of patient cells in the post transplant blood or bone marrow of patients suffering from haematological disorders has the potential to allow early detection of emergent leukaemic populations and thus improve clinical outcome. 
